Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Revenue Recognition

Schedule of disaggregation of revenues

	Three months ended
	March 31,
	2020		2019
(Amounts in thousands)
Product revenues
Sale of genetic tests	$	87,046	$	63,364
Licensing and other
Constellation and paternity		1,367		1,332
License and development services		4,802		148
Other		797		1,980
Licensing and other revenues		6,966		3,460
Total revenues	$	94,012	$	66,824

Schedule of disaggregation of revenues by payer types

	Three months ended
	March 31,
	2020		2019
(Amounts in thousands)
Insurance carriers	$	70,672	$	50,201
Laboratory and other partners		15,683		10,023
Patients		7,657		6,600
Total revenues	$	94,012	$	66,824

Schedule of total revenue by geographic area

	Three months ended
	March 31,
	2020		2019
(Amounts in thousands)
United States	$	86,731	$	60,283
Americas, excluding U.S.		782		818
Europe, Middle East, India, Africa		3,476		4,004
Asia Pacific and Other		3,023		1,719
Total revenues	$	94,012	$	66,824

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	March 31,		December 31,
(Amounts in thousands)	2020		2019
Assets:
Accounts receivable	$	61,577	$	53,351
Liabilities:
Deferred revenue, current portion	$	51,840	$	56,016
Deferred revenue, long-term portion		25,152		23,808
Total deferred revenues	$	76,992	$	79,824

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2019	$	79,824
Increase in deferred revenues		710
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(3,455)
Revenue recognized from performance obligations satisfied within the same period		(87)
Balance at March 31, 2020	$	76,992